OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

PHARMACY RESEARCH UK

TRUSTEES’ REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

CHARITY NO: 1148335

PHARMACY RESEARCH UK

TRUSTEES’ REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

CONTENTS

Page
Reference and Administrative Information 2
Foreword from the Chair 3
Trustees’ Report 4
Independent Examiner’s Report 11
Statement of Financial Activities 12
Balance Sheet 13
Notes to the Financial Statements 14

1

PHARMACY RESEARCH UK TRUSTEES’ REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

REFERENCE AND ADMINISTRATIVE INFORMATION

Registered Charity Number

1148335

Governing Instrument

Pharmacy Research UK is governed by its Charitable Trust Deed dated 5 July 2012

Principal Address

66-68 East Smithfield, London, E1W 1AW

Trustees who have served since 1 January 2025 Raymond Anderson Sue Ashelby Katherine Byrne (appointed 21 April 2026) Ravinder Singh Chahil Professor Brian Edwards Professor Rachel Elliott Malcolm Harrison (Chair) Peter Johnstone (appointed 21 April 2026) Dr Sonja Jonas (appointed 21 April 2026) Tase Oputu Jessica Purkiss Dr Dimitri Varsamis (resigned 17 July 2025)

Chief Executive

Guy Parckar

Research Manager

Ardeshier Mofidi

Independent Examiner

Simon Goodridge FCA, Knox Cropper LLP, 65 Leadenhall Street, London, EC3A 2AD

Solicitors

Boyes Turner LLP, Abbots House, Abbey Street, Reading RG1 3BD

Investment Manager

Investec Wealth & Investment Ltd, 30 Gresham Street, London EC2V 7QN

Bankers

Clydesdale Bank PLC, 91 Gresham Street, London EC2V 7BL

2

PHARMACY RESEARCH UK

FOREWORD FROM THE CHAIR

FOR THE YEAR ENDED 31 DECEMBER 2025

After funding our highest ever level of grant awards in 2024 Pharmacy Research UK (PRUK) made the conscious decision to slightly scale back on new commitments in 2025 in order to help protect our overall funding pot for future years. This turned out to be a particularly prudent decision, as volatile financial markets meant that we also faced a challenging year in terms of returns on the investment portfolio that we use to fund our awards. But we were still able to fund an array of new projects and awards totalling well over £100,000 across the year, while continuing to fund nearly £200,000 of existing awards over the course of 2025.

We also continued to benefit hugely from our partnership working approach – meaning that our committed funds were stretched far further by partner organisations matching or even exceeding our own commitments. This allows us, even as a relatively small funder, to massively amplify our impact, drawing in more funding to pharmacy research through our many brilliant partners. These range from small organisations like the British Oncology Pharmacy Association (BOPA) and the College of Mental Health Pharmacy (CMHP) to huge funders like the National Institute for Health and Care Research (NIHR) and this continues to represent a key element of our strategic approach.

As a member of the Association for Medical Research Charities (AMRC), PRUK’s awards are always assessed to the highest quality standards to ensure we are only ever fund the best, most scientifically robust projects. I am hugely grateful both to our trustee board for their dedication and insight, and to our expert Scientific Advisory Panel for all their invaluable work in supporting the organisation to deliver the best possible outcomes each year with the funding we have available.

In many ways 2025 showed PRUK at its best – making prudent, sensible planning decisions in light of a tough economic climate, but still delivering a suite of new and existing funding awards that will add to and enhance pharmacy research. I believe we can be doubly proud to continue to deliver on our charitable mission through more challenging times, not just in years of bumper economic growth.

Malcolm Harrison

Chair, Board of Trustees, Pharmacy Research UK

3

PHARMACY RESEARCH UK

TRUSTEES’ REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

OBJECTS

The object of Pharmacy Research UK, as set out in its Charitable Trust Deed, is: “To advance the education of the public in general (and particularly amongst scientists) on the subject of pharmacy and to promote research for the public benefit in all aspects of that subject and to publish the useful results.”

VISION AND PURPOSE

Our vision of improving the health of the public through excellence in pharmacy research is a longterm challenge. The following purpose statements outline how we address this challenge:

STRUCTURE, GOVERNANCE AND MANAGEMENT

Pharmacy Research UK is the principal research charity supporting pharmacists and pharmacy to improve healthcare for the benefit of patients and the public. Our broad ambition is to improve the health of the public through supporting and promoting excellence in pharmacy research.

Pharmacy Research UK is a charitable trust established in 2012 and is registered under the Charities Act 2011 (registration number 1148335). Pharmacy Research UK's registered office is 66-68 East Smithfield Street, London, E1W 1AW. Pharmacy Research UK is governed by its Charitable Trust Deed of 5th July 2012.

Our Trustees bring with them a wealth of skills and experience relevant for the work of the charity, including pharmacy and the pharmaceutical sciences, medicine, education, finance, health services, research, business and policy.

4

PHARMACY RESEARCH UK

TRUSTEES’ REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

We consider each of the Trustees to be independent in character and judgments and that there are no relationships or circumstances which are likely to affect, or could appear to affect, the Trustees' judgment.

Apart from where specified in our trust deed, trustees are appointed for an initial term of up to three years by a resolution of the trustees passed at a special meeting. In selecting individuals for appointment as trustees, the trustees must have regard to the skills, knowledge and experience needed for the effective administration of the charity (either the pursuit of its objects or management of the charity).

A Trustee cannot resign unless there are enough trustees remaining in office when the notice of resignation takes effect to form a quorum for meetings (a third of trustees or two trustees, whichever is the greater).

The Board of Trustees sets strategy, decides priorities, establishes funding policies and allocates budgets. The Board of Trustees draws on the advice of the Scientific Advisory Panel in relation to grant making, project management and oversight. Pharmacy Research UK supports high quality pharmacy research across a range of disciplines (social and clinical). Grant making is done through a UK wide competitive process and supported by external expert peer review and overseen by our Scientific Advisory Panel. In the reporting year, Pharmacy Research UK has continued to follow the governance processes established by the AMRC to assure the quality and rigour of our grant review and award processes.

PRUK offers an induction programme for all new Trustees, which includes materials relating to our charitable purposes and finances, the powers of the Trustees and information about day-to-day running of Pharmacy Research UK.

OBJECTIVES FOR THE REPORTING YEAR

At the start of 2025 we set ourselves some clear objectives, in line with delivering our charitable purpose. This is how we delivered on those objectives:

- Building the pharmacy research workforce by supporting the development of research skills among pharmacy professionals:

In 2025 our funding call included offering our full set of developmental awards – these range from small bursaries to support pharmacy professionals in the early stages of their research journey, right up to our flagship PhD programme. In 2025 we received particularly strong applications across our bursary awards and so made the decision to offer above our initial budget in this area. This was ultimately offset by the decision not to fund a new PhD award for 2025, based on the rigorous scientific review of all applications. We will always fund the strongest, most scientifically robust applications, in line with our obligations as a member of the Association of Medical Research Charities (AMRC) – in 2025 that meant a stronger focus on our bursaries, where we received a host of excellent applications.

We also set ourselves a goal for 2025 to “work with sector leadership groups, and others, to support wider initiatives to embed research more fully in pharmacy practice”. We have been particularly active in this area this year – we were a co-signatory to the successful NIHR-funded Pharmacy Research Incubator, with our chief executive sitting on the steering committee for that group. Our chief executive also serves on the Pharmacy Research Advisory Group (PRAG) which was set up with a goal of trying to embed research more fully in pharmacy. As an active and engaged member in both of these key groups, and by maintaining strong relationships across the sector, we have been working hard to help deliver the long-term changes that will help embed research in the pharmacy profession.

5

PHARMACY RESEARCH UK

TRUSTEES’ REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

We have also been able to ensure that PRUK, as the primary dedicated funder of pharmacy research in the UK, has a clear role as this work develops.

We are very hopeful that this wider policy work can help build a landscape within the pharmacy profession in which PRUK’s crucial role continues to grow and develop.

- Supporting high quality research into the practice of pharmacy and the provision of pharmaceutical care that can develop policy and improvements in practice:

We launched our funding call towards the end of 2024, which then closed for applications in March 2025. Once the call has closed we conduct an extensive peer review process on all applications followed by discussion and assessment across our Scientific Advisory Panel (SAP). This culminates in recommendations for funding and final decisions at our July trustee board meeting. This rigorous, intensive process means we can be confident that we are only funding the strongest, most scientifically robust awards.

Having funded a higher level of awards than ever before in 2024 we took the decision to scale back slightly and reduce our new commitments in 2025. Primarily this meant not running some of our larger partnership awards, for example our award with Diabetes UK. The nature of our funding means that awards committed in one year tend to be paid out over an extended period of several years ahead – for our PhD awards, for example, we may well still be paying out elements of a grant as long as 6 years after the initial award was made. This means that a decision not to run an award in one year will show a financial benefit several years afterwards – it also means that, for example, despite not offering a new partnership award in 2025, we are quite likely still be paying towards a previously awarded grant. So not offering a new award does not mean stopping all funding activity in that area.

All of this means that, in 2025, we have continued both to fund new awards, albeit primarily focused on our smaller developmental grants, but also have continued funding our existing commitments across a huge range of different areas – this includes the final tranche of funding for our Diabetes UK award, and the funding towards our fantastic partnership awards with Kidney Research UK.

- Entering partnerships to amplify the value and reach of pharmacy research:

Working in partnership remains a cornerstone of PRUK’s activity. In 2025 we funded new partnership awards with the likes of the British Oncology Pharmacy Association (BOPA) and the National Institute for Health and Care Research (NIHR). We also continued to fund awards with many other partners, and also saw the funding go out for a brilliant set of new awards delivered jointly with Kidney Research UK.

Whenever we work in partnership we are able to bring our own expertise and connections across pharmacy, as well as an open, collegiate approach to joint-working that has helped deliver fantastic outcomes over many years. This approach has served us exceptionally well, allowing us as a small organisation to leverage vastly more funds into pharmacy research than we could deliver on our own. Over the medium-term our next challenge will be both to continue to build on this, whilst also starting to add some additional income streams to add to our own offer. If we can work in partnership wherever possible we can hopefully both draw additional funds into pharmacy research, and also stretch our own capacity to fund even further.

6

PHARMACY RESEARCH UK

TRUSTEES’ REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

As well as funding pharmacy professionals to conduct research, PRUK also publishes the final reports from our projects on our website, and also supports pharmacy professionals to promote their findings.

We have a range of tools to help with this, including access to the AMRC’s Open Research platform, and our own Impact Fund. This is a small discretionary fund that PRUK administer that aims to support people to deliver impact from their research (whether that is PRUK funded research or not). This could involve anything from presenting the research at a conference, publishing it in a journal, or supporting work to help embed the findings of research at a local level.

As a relatively small funder we are also conscious of the fact that we are not able to fund the huge trials that are often needed to embed major practice change. Because of this we work very hard to ensure that we can help maintain a pathway for researchers – our bursaries often fund first steps into research, our developmental awards can help establish a project in a particular area of work, our NIHR partnership is aimed at readying researchers for their PhDs, our PhD studentship supports a pharmacy professional through their doctorate. All of these, together with our wider support schemes like mentoring, have allowed us to support projects in an early stage that have gone on to secure major national-level funding to deliver real impact on practice.

- Identifying opportunities to maximise and diversify PRUK’s income streams:

Our partnership work has been instrumental in helping to stretch and amplify our reach and impact. But as a funder we are still very reliant on the returns on our investment to continue to make new awards. In a difficult economic climate this becomes even more apparent and does mean that we always have to manage and balance what we are able to offer from the resources we have available.

As a result of this 2025 saw us begin a longer-term piece of work to look at how we can potentially expand and diversify the funding that we have available. As a first stage we undertook some significant improvements to the PRUK website in 2025, improving the look, feel and navigability of the site. This work is ongoing, and we have more plans to enhance the site in 2026. We have also begun using a database of potential grant funders, and begun submitting applications for additional funding for our work, and begun making contact with other likeminded organisations that could potentially support new or existing awards that we make.

This work is long-term, and we hope will bear more fruit in coming years, but is very much a key part of our plans for long-term sustainability. The fact that we maintain very healthy reserves we hope will be an attraction to potential funders, who can be assured that they are supporting an active, sustainable organisation. Funding can go direct to supporting our unique work as the only dedicated funder of pharmacy practice research in the UK, safe in the knowledge that our sound finances can continue to cover our operating costs.

7

PHARMACY RESEARCH UK

TRUSTEES’ REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

PLANS FOR THE FUTURE

In 2026 we will continue to make sensible, prudent decisions about our funding offers, while also offering awards to support our full research pathway for pharmacy professionals. Fundamentally this means maintaining our full funding call offering and continuing to support our long-term partnership awards, while also managing our funds carefully to ensure long-term sustainability.

However we expect to add to this with a range of other activities, including continuing our work within the sector with partners like the NIHR-funded Pharmacy Research Professionals Incubator and the Pharmacy Research Advisory Group. Through this work we will be identifying actions that can help support more pharmacy professionals to engage in research. We expect this to include building a new ‘hub’ section on our website, providing a first port of call for any pharmacy professional interested in research, as well as running a ‘showcase event’ highlighting and celebrating successes in building research capacity.

We also expect to build on our initial steps into further income generation and to develop a new strategic focus to take the organisation into the next few years of work. Doing this alongside maintaining all our core work of delivering high-quality research funding means an exciting year awaits PRUK in 2026. More specifically this will involve:

- Building the pharmacy research workforce by supporting the development of research skills among pharmacy professionals:

- Supporting high-quality research into the practice of pharmacy and the provision of pharmaceutical care that can develop policy and improvements in practice:

- Using and promoting research to highlight the important role of pharmacy and pharmacy professionals in health provision:

8

PHARMACY RESEARCH UK

TRUSTEES’ REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

FINANCIAL REVIEW

Full details of income and expenditure for the year are shown in the Statement of Financial Activities set out on page 12.

PUBLIC BENEFIT

The trustees have referred to the Charity Commission’s guidance on public benefit when reviewing their aims and objectives and planning their future activities.

RESERVES POLICY

Total funds at the year-end were £2,665,305 (2024 £2,813,326) including endowment and restricted funds as set out on page 13.

Free reserves or unrestricted funds amounted to £2,304,099 (2024 £2, 448,917). The unrestricted funds are mainly represented by a share of the investment portfolio which is held for the longer term to provide income to the charity out of which it pays for research and other project work.

INVESTMENT POLICY

The charity has power to invest in such assets as it sees fit. The Trustees have appointed Investec as investment managers to manage the charity’s investment assets, with a brief to adopt a medium risk investment strategy whilst providing revenue for the charity’s current needs while enhancing income and capital growth over the long term.

The trustees have adopted an ethical investment and fundraising policy and in particular this makes clear that the trustees do not believe it would be appropriate for Pharmacy Research UK to receive income from the tobacco industry.

GOING CONCERN

The Board of Trustees is of the opinion that the charity has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties regarding the Trust’s ability to do so.

KEY MANAGEMENT PERSONNEL

The Trustees consider the board of trustees and the senior management team to comprise the key management personnel of the charity in charge of directing and controlling, running and operating the Charity on a day to day basis.

Details of trustees’ expenses are disclosed in note 5 to the financial statements.

9

PHARMACY RESEARCH UK

TRUSTEES’ REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

RISK MANAGEMENT

The Trustees have assessed the major risks to which the charity is exposed, in particular those risks related to the operations and finances of the charity, and are satisfied that systems are in place to mitigate exposure to the major risks, although it is recognized that systems can only provide reasonable, and not absolute, assurance. These systems are reviewed at least once every year. The Trustees’ have identified the following risks:

Risk identified

Action taken to mitigate the risk

Investments will drop in value Trustees have appointed investment advisors to manage the investments Donations made will not be spent how the Trustees actively review donations and ask for Trustees would like updates and reports

TRUSTEES’ RESPONSIBILITIES STATEMENT

The Trustees are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the charity and of the incoming resources and application of resources of the charity for that period.

In preparing these statements the Trustees are required to:

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Trustees and signed on behalf of the Trustees by:

Malcolm Harrison, Chair of Trustees

Dated: 21[st] October 2026

10

INDEPENDENT EXAMINER’S REPORT TO THE TRUSTEES OF PHARMACY RESEARCH UK

I report to the trustees on my examination of the accounts of Pharmacy Research UK for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity’s trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (the Act).

I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner’s statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material aspect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Simon Goodridge FCA Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD

Date 28 October 2026

11

PHARMACY RESEARCH UK

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2025

Note
Income from:
Investments
2
Charitable Activities
Other income
Total Income
Expenditure on:
Raising funds
3
Charitable activities
3
Total Expenditure
Net (Expenditure) before
gains on investments
Net Gains/(Losses) on
Investments
7
Net income/(expenditure)
Transfers between funds
11
Net Movement in Funds
Total Funds Brought
Forward
Total Funds Carried Forward
Unrestricted
Restricted
Endowment
Total
Total
Funds
Funds
Funds
2025
2024
£
£
£
£
£
71,749
2,871
-
74,620
82,813
-
4,921
-
4,921
7,260
6,967
-
-
6,967
-
78,716
7,792
-
86,508
90,073
19,885
798
-
20,683
22,247
335,932
22,598
-
358,530
398,561
355,817
23,396
-
379,213
420,808
(277,101)
(15,604)
-
(292,705)
(330,735)
139,099
954
4,631
144,684
147,257
(138,002)
(14,650)
4,631
(148,021)
(183,478)
(6,816)
6,816
-
-
-
(144,818)
(7,834)
4,631
(148,021)
(183,478)
2,448,917
103,360
261,049
2,813,326
2,996,804
2,304,099
95,526
265,680
2,665,305
2,813,326

12

PHARMACY RESEARCH UK

BALANCE SHEET AS AT 31 DECEMBER 2025

Note
FIXED ASSETS
Investments
7
CURRENT ASSETS
Debtors
8
Cash at Bank
CURRENT LIABILITIES
Creditors: amounts falling due within
one year
9
NET CURRENT ASSETS
/(LIABILITIES)
TOTAL ASSETS LESS CURRENT
LIABILITIES
Creditors : amounts falling due after
more than one year
10
NET ASSETS
12
REPRESENTED BY
Endowment funds
Restricted funds
Unrestricted funds
TOTAL FUNDS
11
2025
£
£
2,959,786
-
30,590
30,590
(142,581)
(111,991)
2,847,795
(182,490)
2,665,305
265,680
95,526
2,304,099
2,665,305
2025
£
£
2,959,786
-
30,590
30,590
(142,581)
(111,991)
2,847,795
(182,490)
2,665,305
265,680
95,526
2,304,099
2,665,305
2024
£
£
3,036,186
2,942
37,706
40,648
(183,076)
(142,428)
2,893,758
(80,432)
2,813,326
261,049
103,360
2,448,917
2,813,326
2024
£
£
3,036,186
2,942
37,706
40,648
(183,076)
(142,428)
2,893,758
(80,432)
2,813,326
261,049
103,360
2,448,917
2,813,326
30,590
(142,581)
40,648
(183,076)
2,847,795
(182,490)
2,893,758
(80,432)
2,665,305 2,813,326
265,680
95,526
2,304,099
261,049
103,360
2,448,917
2,665,305 2,813,326

Approved by the Trustees and signed on behalf of the Trustees by:

Malcolm Harrison, Chair of Trustees

Dated: 21[st] October 2026

13

PHARMACY RESEARCH UK NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting Policies

1.1 Basis of preparation of Financial statements

The financial statements are prepared under the historical cost convention with the exception of investments which are included at market value. The financial statements have been prepared in accordance with the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (Charities SORP (FRS 102 second edition – effective 1 January 2019)) and applicable UK accounting standards.

Pharmacy Research UK meets the definition of a public benefit entity under FRS 102.

1.2 Going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements.

The trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.

1.3 Incoming recognition

All incoming resources are included in the Statement of Financial Activities when the charity has entitlement to the funds, certainty of receipt and the amount can be measured with sufficient reliability.

Costs borne by the Royal Pharmaceutical Society on behalf of Pharmacy Research UK are reflected as income, classified as donations and as expenditure in the appropriate categories where the gift in kind to the charity can be appropriately valued.

Grants have been accounted for when receivable by the charity.

1.4 Expenditure recognition

Grants payable to further charitable objectives are outflows of resources in respect of grants for training and research.

Research costs relate to the charity’s costs associated with pharmacy research plus an allocation of support costs.

Governance costs are costs associated with constitutional and statutory requirements, eg the costs of trustee meetings and in connection with the statutory accounts. These and other support costs are allocated across the charitable activities

1.5 Investments

Investments are a form of basic financial instrument and are shown in the financial statements at market value. Movements in the market values of investments are shown as investment gains and losses in the Statement of Financial Activities.

14

PHARMACY RESEARCH UK NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

1.6 Funds

Unrestricted funds represent unrestricted income which is expendable at the discretion of the Trustees in furtherance of the objects of the Charity.

Restricted funds are subject to specific conditions imposed by the donor or by the specific terms of a trust deed or other legal measures.

Expendable endowment funds represent assets which have the restriction that the revenue generated by holding the asset is available to spend but the capital itself cannot be spent. Income generated from endowment funds is applied to restricted funds as appropriate.

1.7 Estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the trustee’s best knowledge of the amount, events or actions, actual results may ultimately differ from these estimates. The Trustees do not consider there to be any material estimates and judgements.

1.8 Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including debtors and creditors, are initially recognized at transaction value and subsequently measured at their settlement value.

2. INVESTMENT INCOME

Income from
listed
investments
Interest
receivable
Unrestricted
Funds
£
71,749
258
71,749
Restricted
Funds
£
2,871
-
2,871
Endowment
Funds
£
-
-
-
Total
2025
£
74,362
258
74,620
Total
2024
£
81,903
910
82,813

15

PHARMACY RESEARCH UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

3. EXPENDITURE

CURRENT YEAR

Direct costs
£
Raising funds
Investment
managers
20,683
Charitable activities
Research Funding
Staff costs
72,828
Other costs
-
72,828
RIOR YEAR
Direct costs
£
Raising funds
Investment
managers
22,247
Charitable activities
Research Funding
Staff costs
67,024
Other costs
10,118
77,142
Grants
£
-
-
223,972
223,972
Grants
£
-
-
261,331
261,331
Support
Costs
£
-
46,123
15,606
61,729
Support
Costs
£
-
48,588
11,500
60,088
Total
2025
£
20,683
118,951
239,578
358,530
Total
2024
£
22,247
115,612
282,949
398,561
Total
2024
£
22,247
115,612
282,949
398,561

PRIOR YEAR

4. SUPPORT COSTS

Staff costs
Governance (note 6)
Other support costs
Total
2025
£
46,123
10,091
5,515
61,729
Total
2024
£
48,588
7,930
3,570
60,088

16

PHARMACY RESEARCH UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

5. STAFF COSTS

AFF COSTS
The staff costs are analysed as follows:
Wages and salaries
Social security
Pension costs
Total
2025
£
100,555
13,351
5,045
118,951
Total
2024
£
100,039
10,730
4,843
115,612

No employee earned total emoluments in excess of £60,000 per annum during the year under review.

Number of employees 2025
Number
3
2024
Number
3

The charity’s key management personnel comprise the chief executive and the trustees who were unpaid. The costs of key management personnel for the year was £52,274 (2024: £51,973).

The Trustees did not receive any remuneration during the year. The trustees were reimbursed expenses in the year totalling £180 (2024: £370).

6. GOVERNANCE COSTS

Trustee expenses
Legal & Professional fees
Independent examination
Independent examiner- other services
Total
Total
2025
2024
£
£
180
370
2,131
120
6,700
6,360
1,080
1,080
10,091
7,930

7. INVESTMENTS

Listed investments
Market value at 1 January 2025
Acquisitions at cost
Proceeds from disposals
Investment gains and losses
Market value at 31 December 2025
Cash held by investment managers for
reinvestment
Total
2025
£
3,026,075
3,226,819
(3,439,343)
144,684
2,958,235
1,551
2,959,786
Total
2024
£
3,055,565
556,897
(733,644)
147,257
3,026,075
10,111
3,036,186

Investments mainly comprise listed investments on international stock exchanges at market value within an investment portfolio managed by Investec Wealth & Investment.

17

PHARMACY RESEARCH UK NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

8. DEBTORS

Prepayments and accrued income
REDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Accruals and deferred income
Grant commitments (see note 10)
Total
2025
£
-
Total
2025
£
18,261
124,320
142,581
Total
2024
£
2,942
Total
2024
£
11,960
171,116
183,076

9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

10. GRANT COMMITMENTS

Grants falling due in less than one year
Grants falling due in more than one year
Total
2025
£
124,320
182,490
306,810
Total
2024
£
171,116
80,432
251,548

11. STATEMENT OF FUNDS

Endowment
Galen Trust
Restricted funds
Leverhulme
Bursary
Galen Trust
Leverhulme Award
HSRPP
BOPA
CMHP
General fund
Balance at
1 January
2025
£
261,049
1,398
57,994
26,750
15,171
2,240
(193)
103,360
2,448,917
2,813,326
Income
£
-
-
2,871
-
-
4,921
-
7,792
78,716
86,508
Expenditure
£
-
-
(9,214)
-
(2,625)
(9,868)
(1,689)
(23,396)
(355,817)
(379,213)
Investment
Gains/(losses)
and transfers
£
4,631
-
954
-
-
4,934
1,882
7,770
132,283
144,684
Balance at
31 December
2025
£
265,680
1,398
52,605
26,750
12,546
2,227
-
95,526
2,304,099
2,665,305

18

PHARMACY RESEARCH UK NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

11. STATEMENT OF FUNDS (continued)

Leverhulme Bursary

Bursaries are made annually to develop individual community pharmacists’ skills and careers in research.

Galen Trust

Awards are made annually to individual pharmacist researchers. This is funded by the Galen Endowment through the Galen Trust.

Leverhulme Award

Awards are made annually for research that is of benefit to community pharmacy.

Health Services Research & Pharmacy Practice (HSRPP)

An annual conference to support novice pharmacist researchers and showcase pharmacy research.

BOPA

A collaborative project with the British Oncology Pharmacy Association (BOPA) – A registered charity promoting excellence in the pharmaceutical care of patients with cancer through education, communication and research

CMHP

A partnership with the College of Mental Health Pharmacy, a charity which aims to benefit individual care through advancing education and research in the practice of mental health pharmacy.

Transfers represent the charity’s contributions towards the funding partnerships with BOPA and CMHP.

Prior year movements in funds

Endowment
Galen Trust
Restricted funds
Leverhulme
Bursary
Galen Trust
Leverhulme Award
HSRPP
BOPA
CMHP
General fund
Balance at
1 January
2024
£
256,632
6,253
54,135
26,750
23,630
(99)
(193)
110,476
2,629,696
2,996,804
Income
£
-
-
3,276
-
-
7,260
-
10,536
79,537
90,073
Expenditure
£
-
(4,855)
(890)
-
(8,459)
(9,842)
-
(24,046)
(396,762)
(420,808)
Investment
Gains/(losses)
and transfers
£
4,417
-
1,473
-
-
4,921
-
6,394
136,446
147,257
Balance at
31 December
2024
£
261,049
1,398
57,994
26,750
15,171
2,240
(193)
103,360
2,448,917
2,813,326

19

PHARMACY RESEARCH UK NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

12. ANALYSIS OF NET ASSETS BETWEEN FUNDS

Current year

Investments
Net current
assets/(liabilities)
Long term
liabilities
ior year
Investments
Net current
assets/(liabilities)
Long term
liabilities
Unrestricted
Funds
£
2,836,991
(374,130)
(158,762)
2,304,099
Unrestricted
Funds
£
2,918,976
(389,627)
(80,432)
2,448,917
Restricted
Funds
£
20,980
98,274
(23,728)
95,526
Restricted
Funds
£
20,026
83,334
-
103,360
Endowment
Funds
£
101,815
163,865
-
265,680
Endowment
Funds
£
97,184
163,865
-
261,049
Total
2025
£
2,959,786
(111,991)
(182,490)
2,665,305
Total
2024
£
3,036,186
(142,428)
(80,432)
2,813,326

Prior year

13. TRANSACTIONS WITH RELATED PARTIES

Pharmacy Research UK is hosted by the Royal Pharmaceutical Society which during the year provided office accommodation without charge to Pharmacy Research UK. The charity is unable to put a reliable value on the office accommodation provided for free and so this is not reflected in Pharmacy Research UK’s financial statements.

There were no other related party transactions in the year (2024: none).

20

PHARMACY RESEARCH UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

14. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

Note
Income from:
Investments
2
Charitable Activities
Other income
Total Income
Expenditure on:
Raising funds
3
Charitable activities
3
Total Expenditure
Net (Expenditure) before
gains on investments
Net Gains/(Losses) on
Investments
7
Net income/(expenditure)
Transfers between funds
11
Net Movement in Funds
Total Funds Brought
Forward
Total Funds Carried Forward
Unrestricted
Restricted
Endowment
Total
Funds
Funds
Funds
2024
£
£
£
£
79,537
3,276
-
82,813
-
7,260
-
7,260
-
-
-
-
79,537
10,536
-
90,073
21,357
890
-
22,247
375,405
23,156
-
398,561
396,762
24,046
420,808
(317,225)
(13,510)
-
(330,735)
141,367
1,473
4,417
147,257
(175,858)
(12,037)
4,417
(183,478)
(4,921)
4,921
-
-
(180,779)
(7,116)
4,417
(183,478)
2,629,696
110,476
256,632
2,996,804
2,448,917
103,360
261,049
2,813,326

21